Multiomics data of cancer patients and cell lines, in synergy with deep learning techniques, have aided in unravelling predictive problems related to cancer research and treatment. However, there is still room for improvement in the performance of the existing models based on the aforementioned combination. In this work, we propose two models that complement the treatment of breast cancer patients. First, we discuss our deep learning-based model for breast cancer subtype classification. Second, we propose DCNN-DR, a deep convolute.ion neural network-drug response method for predicting the effectiveness of drugs on in vitro and in vivo breast cancer datasets. Finally, we applied DCNN-DR for predicting effective drugs for the basal-like breast cancer subtype and validated the results with the information available in the literature. The models proposed use late integration methods and have fairly better predictive performance compared to the existing methods. We use the Pearson correlation coefficient and accuracy as the performance measures for the regression and classification models, respectively.